The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

dc.date.accessioned	2023-03-06T07:32:59Z
dc.date.available	2023-03-06T07:32:59Z
dc.date.issued	2022
dc.identifier.citation	Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100505
dc.relation.isversionof	10.1097/CAD.0000000000001310
dc.relation.isversionof	10.1097/CAD.0000000000001310
dc.title	The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
dc.relation.journal	Anticancer Drugs
dc.identifier.doi	10.1097/CAD.0000000000001310
dc.contributor.author	Özdemir Ö
dc.contributor.author	Özdemir Ö
dc.contributor.author	Zengel B
dc.contributor.author	Yildiz Y
dc.contributor.author	Uluç BO
dc.contributor.author	Cabuk D
dc.contributor.author	Ozden E
dc.contributor.author	Salim DK